Where does Werewolf Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Werewolf Therapeutics, Inc. ranks #27,817 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Werewolf Therapeutics, Inc. hold?

Werewolf Therapeutics, Inc. holds 10 US utility patents granted between 2020 and 2025, spanning 5 technology areas.

What is Werewolf Therapeutics, Inc.'s Innovation Score?

Werewolf Therapeutics, Inc. has an Innovation Score of 46.0 out of 100 (top 22% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Werewolf Therapeutics, Inc. focus on?

Werewolf Therapeutics, Inc.'s top technology area is C07K (Peptides) with 10 patents. Grants appear in 5 CPC subclasses total.

Is Werewolf Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Werewolf Therapeutics, Inc..

What does claim depth mean for Werewolf Therapeutics, Inc.'s patents?

Werewolf Therapeutics, Inc.'s patents average 16.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Werewolf Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Werewolf Therapeutics, Inc.

USPTO PatentsView assignee record - 10 granted patents across 5 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Werewolf ranks #27,817 of 49,997 tracked US assignees by granted-patent volume, with 10 patents across 5 technology areas.

#27,817
of 49,997 US assignees by volume: Top 22%
by Innovation Score (46.0/100): 16.4
avg claims per patent

USPTO PatentsView assignee plate

Corpus R27817 · US Corporation #27,817 · 10 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 10 grants
MID-PACK #27,817/49,997
PHOTO-FINISH Wavin B V
CPC-NARROW C07K · 5 areas
INNOV-PAR 46.0/100
CLAIMS-RICH 16.4 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2020–2025 · 6y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Wavin B.V. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Werewolf Therapeutics · this assignee

46
3D Lighting… · lowest

7

What this shows Werewolf's Innovation Score is 46.0/100 (top 22% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Werewolf's grants concentrate

Werewolf Therapeutics, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2022 (3 grants) versus a trough of 1 in 2023. By volume, Werewolf sits between WWS Acquisition, LLC and WinTech Polymer Ltd..

Werewolf's three-year grant acceleration

Werewolf Therapeutics, Inc. shows 7 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

WWS Acquisition

10
Wavin B V

10
Wellworx Energy S…

10
Wellbore Integrit…

10
West Virginia Uni…

10
Wetend Oy

10
Wicue USA

10
Wintech Polymer

10
Werewolf Therapeu… ◀

10

What this shows Werewolf holds 10 patents at rank #27,818, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Werewolf

By rank, the assignees closest to #27,818 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Werewolf's primary technology class.

Werewolf's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

46 Top 22% higher than 78% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

Werewolf Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	2	20.0%
2022	3	30.0%
2023	1	10.0%
2024	3	30.0%
2025partial year	1	10.0%

Which technologies does Werewolf Therapeutics, Inc. patent most?

C07K - Peptides 10

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 10

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 6

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 2

C12Y - Enzymes 1

Top 5 of 5 technology areas

Where it ranks

Overall rank by patents

#27,817

of 49,997 tracked assignees

Innovation Score

46.0 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Werewolf Therapeutics, Inc.'s patent record in context - here's where to go next.

Werewolf Therapeutics, Inc.'s lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #27,817 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Werewolf Therapeutics, Inc. against WWS Acquisition, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 46.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.